What DENTSPLY SIRONA’s latest earnings mean for shareholders

DENTSPLY SIRONA (XRAY) is in focus after its second quarter 2026 results showed lower sales but a shift back to profit, alongside reaffirmed full year sales guidance and an ongoing share buyback program.

The latest earnings and guidance sit against a mixed share price picture for DENTSPLY SIRONA. The 90 day share price return of 15.09% suggests some renewed interest, yet the 1 year total shareholder return has declined 13.99% and the 5 year total shareholder return is down 78.45%. Momentum from recent gains therefore contrasts with a weaker longer term record.

If the latest results have you rethinking where growth and risk sit in your portfolio, it could be a good time to scan for other healthcare technology opportunities through 44 healthcare AI stocks

After a sharp multi year share price fall and a recent 90 day rebound, DENTSPLY SIRONA now sits at a very different entry point. Does the current valuation still leave more upside potential than downside risk for new buyers?

Most Popular Narrative: 13.5% Undervalued

The most followed narrative for DENTSPLY SIRONA sees fair value at $13.40, above the last close of $11.59, and links that gap to a profit recovery story backed by higher margins and a lower discount rate.

Active cost reduction programs, operational streamlining, and supply chain optimization are in progress, with management indicating a stronger urgency to go "deeper and faster," potentially boosting EBITDA margin and cash flow generation through both lower SG&A and more efficient manufacturing.

Analysts are not just guessing on DENTSPLY SIRONA. Their fair value narrative leans on steadier revenue, higher margins, and a future earnings profile that looks very different to today. Curious which assumptions carry the most weight in that shift and how they link back to the current discount.

Result: Fair Value of $13.40 (UNDERVALUED)

However, the DENTSPLY SIRONA narrative still faces clear risks, including ongoing revenue softness in key markets and tariff cost pressures that could further squeeze margins.

Next Steps

Feeling cautious or encouraged by the DENTSPLY SIRONA story so far? Take a moment to review the numbers yourself and stress test the assumptions. Then weigh those figures against the 3 key rewards

Looking for more investment ideas beyond DENTSPLY SIRONA?

If DENTSPLY SIRONA has sharpened your focus on quality, do not stop there. Use the Simply Wall Street Screener to widen your watchlist with focused, data driven ideas.

• Target reliable income by reviewing companies with strong payouts and balance sheets through the 10 dividend fortresses.
• Spot potential value opportunities early by scanning companies that combine quality fundamentals with attractive pricing using the screener containing 18 high quality undiscovered gems.
• Prioritise resilience by filtering for companies that show steadier risk profiles with the 83 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.